Discover the site

Late-Breaking Abstract submission deadline extended

The WCD 2023 Scientific Committee recognizes that the results of certain basic or clinical research projects may not be ready by the general abstract submission deadline. Hence, we are offering a call for Late-Breaking Abstract submission for work that is completed after the general abstract submission deadline. We will prioritise novel and interesting abstracts that will enrich the scientific programme. The Late-Breaking deadline is not intended to offer a second deadline for regular abstract submission. In view of the numerous requests received, the deadline has been extended as shown below:

Late-Breaking Abstract
Submission Opening
14th March 2023 (SGT)

Late-Breaking Abstract
Submission Closing
23rd March, 2023 (SGT)

Late-Breaking Abstract
Acceptance Notification
Starting from April, 2023



  1. Authors are required to indicate their preference for either ORAL or POSTER presentation by checking the appropriate box on the submission web page. The WCD Free Communications Committee will make the final decision on the format of the presentation (i.e. oral or poster). A few selected posters will be scheduled for short oral poster presentations.
  2. Abstracts cannot be identical to any abstracts which have been previously presented at a major international meeting prior to the WCD 2023, or been published in peer-reviewed journals at the time of abstract submission to WCD2023. An update of the study is, however, acceptable and authors should indicate this in the abstract title.
  3. Abstracts will be peer reviewed and ranked according to their scholarly and/or research validity, educational value, clarity of presentation and potential impact on global dermatology.
  4. Acceptance of abstracts will be communicated via e-mail to the corresponding author. The Free Communication Committee’s decision is final and cannot be appealed.
  5. Instructions on the preparation of posters or oral presentation and information about projection facilities will be included with the notification of acceptance.
  6. Submission of an abstract indicates that:
    • the author(s) agree to comply with the abstract submission and presentation rules;
    • the author(s) confirm that the presentation is based on scientific and/or clinical methods that are ethical and valid;
    • all authors have contributed to and approved the abstract in its entirety
  7. Accepted abstracts will be published electronically on digital media and on the WCD 2023 website, and distributed to all delegates.
  8. Accepted abstracts are official communications of the Congress.
  9. The presenting author agrees to register, to attend the Congress, and to present the abstract as scheduled by the WCD. The presenting author must register for the WCD by 15th May 2023, before the abstract can be accepted for inclusion in the final scientific programme and programme book.

Instructions for abstracts preparation

  1. Abstracts must be written and presented in English. Abstracts that are not written in comprehensible English will be rejected and/or returned to the author(s) for revision.
  2. Abstract must be uploaded in WORD format (.doc; .docx)
  3. Title, authors’ names, authors’ affiliation, and presenting author must be provided by filling the online form
    • Title: Use a concise descriptive title that indicates the content of the abstract. Please minimize the use of abbreviations in the title. Commercial trade names for drugs, devices, products, and services should NOT be used in the title.
    • Author: The full name and the full surname for each author must be provided. Do not include degrees or titles.
    • Affiliations: Each author should be listed by department, institution, city, and country.
  4. The body of the abstract text should not exceed 300 WORDS. The online submission program will automatically not allow submissions that do not fit this requirement. Symbols including superscripts and subscripts can be entered in the online system.
  5. The body of the abstract text must be divided into the following subheadings as appropriate. Each sub-heading should be in bold text, begin on a new line, and followed by a colon and space (:). The text for each sub-section should begin immediately after the colon and space (see sample abstract below).

For clinical or investigative studies:

  • Introduction:
  • Objectives:
  • Materials and Method:
  • Results:
  • Conclusions:

For case reports or case series:

  • Background:
  • Observations:
  • Key message

It is NOT sufficient to simply state that “The results will be discussed.” Only common and standard abbreviations may be used without definition. NO REFERENCES, TABLES, CHARTS OR IMAGES ARE ALLOWED. Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted. Drugs, devices, products, and services should be identified by generic names only within the abstract. The use of commercial drug names, brands and registered trademarks are strictly prohibited. No mention of pharmaceutical company names should be included in the abstract. Data must be given in units (International metric system is preferred) that are generally accepted in scientific publications. All co-authors must agree with the submitted results and conclusions, and consent to being listed as authors. Work involving humans or animals, or material derived from them must have been approved by an institutional ethics committee

Abstract topics

For reviewing and scheduling purposes, abstracts will be classified into thematic areas. Please indicate on the submission webpage the appropriate topic classifications to which your abstract belongs. Only 1 thematic category may be chosen. The WCD Free Communications Committee will attempt to respect the authors’ choice regarding their self-selection to a specific topic, but reserves the right to change the allocation in order to achieve a well-balanced scientific program.


  1. Acne, Hidradenitis suppurativa, Rosacea
  2. Aesthetic and Cosmetic dermatology, and Lasers
  3. Artificial intelligence
  4. Atopic dermatitis
  5. Autoimmune blistering diseases
  6. Contact dermatitis
  7. COVID-related dermatoses/vaccine reactions
  8. Cutaneous adverse drug reactions
  9. Cutaneous lymphomas
  10. Dermatologic surgery
  11. Dermatology in elderly patients
  12. Dermatology in women and during pregnancy
  13. Dermatopathology
  14. Dermoscopy & Trichoscopy
  15. Education in dermatology
  16. Epidemiology
  17. Ethics, Quality of care, Quality of life and Costs in dermatology
  18. Hair disorders
  19. Medical dermatology (Granulomatous diseases /Autoinflammation, SAPHO, PAPA and Neutrophilic dermatoses / Eosinophilic dermatoses)
  20. Melanoma and naevi
  21. Mucosal diseases / Skin manifestations of internal diseases
  22. Nail disorders
  23. Novel Medical therapies
  24. Oncology and Transplant dermatology (including CADR to novel chemo and immune-therapies)
  25. Paediatric dermatology, Genetics and Genodermatoses
  26. Phlebology and Vascular disorders
  27. Photobiology and Phototherapy
  28. Physical therapies (PDT, cryotherapy, iontophoresis, DCP)
  29. Pigmentary disorders
  30. Pruritus and dysaesthesias
  31. Psoriasis
  32. Psychodermatology
  33. Rheumatologic dermatology
  34. Sexually transmitted infections and HIV
  35. Skin aging: Extrinsic and intrinsic factors
  36. Skin cancer excluding melanoma
  37. Skin imaging other than dermoscopy
  38. Skin infections, Tropical dermatology, Skin diseases affecting Migrants and Refugees
  39. Skin of colour
  40. Social media, Patient Support Groups and Engagement
  41. Sweat disorders
  42. Teledermatology
  43. Translational science
  44. Urticaria and Angioedema
  45. Vasculitis and Vasculopathies
  46. Wound healing & Keloids

Download in PDF

Important Deadlines

Online Abstract Submission will be available on the Congress website until 23rd March 2023. Please follow the instructions detailed on the website. Your abstract submission will be acknowledged automatically by email, but this confirmation does not constitute official acceptance for presentation.

Fax Submissions Will Not Be Accepted

Submitted abstract can be modified until 23rd March 2023 (extended late breaking abstract submission deadline). Please remove the abstract previously submitted and upload the new document. Authors who wish to withdraw their abstract must send a written request to: wcd2023abstract@thetriumph.com

Acceptance Notification

Authors will be notified from April 2023 as to the acceptance status of their submissions. This includes the assignment of session category and presentation format (oral or poster). Detailed instructions regarding requirements and instructions for oral and poster presentations will also be provided at that time. If your abstract is accepted, you must register no later than 15th May 2023. Unless you register by that date, your abstract will not be included in any WCD print or online publications or the programme book.

Download the abstract sample (docx)
Copyright & Embargo Policy (pdf)

Subscribe to our Newsletter